Protara Therapeutics, Inc. (TARA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.94-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TARA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TARA — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition. On August 11, 2026, Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), o…
Why it matters: Starting this trial is crucial for expanding TARA-002's use in bladder cancer.
Supportive ifADVANCED-3 trial initiated in 2H 2026.
Worry ifThe ADVANCED-3 trial did not start as planned.
Why it matters: If health care revenue growth speeds up, it may help Protara's performance. A strong sector can lift all companies.
Supportive ifHealth care sector revenue growth returns to above 10% year over year.
Worry ifHealth care sector revenue growth remains below 10% year over year.
Why it matters: High cash burn can limit future funding options. Investors need to see improvement.
Worry ifOperating cash burn decreases from -$21.3M in Q1 2026 to a lower amount.
Less concerning ifCash burn increases or remains at -$21.3M or worse in Q2 2026.
Why it matters: Interim results will show how well TARA-002 works in bladder cancer.
Watch forGood interim results were reported in Q1 2026.
Also watch forBad interim results were reported in Q1 2026.
Why it matters: Completing enrollment is key for TARA-002's potential approval in NMIBC. It shows progress in clinical development.
Supportive ifEnrollment in the BCG-Unresponsive group of the ADVANCED-2 trial ends by 4Q 2026.
Worry ifEnrollment is not finished by 4Q 2026. This shows delays in clinical progress.
Why it matters: Managing cash burn is crucial for survival in clinical development. High cash burn can limit future projects.
Worry ifOperating costs go down or cash burn improves from earlier quarters.
Less concerning ifOperating costs go up or cash burn worsens from earlier quarters.
Why it matters: The Chief Medical Officer's departure may change how the trial runs.
Worry ifNo delays or issues arise in the ADVANCED-2 trial following the CMO's departure.
Less concerning ifDelays or setbacks in the ADVANCED-2 trial occur after the CMO's departure.
Why it matters: The BLA submission is an important step for getting TARA-002 approved to treat LMs.
Supportive ifBLA submission for TARA-002 in LMs is filed as planned in 2H 2027.
Worry ifBLA submission is delayed or not filed in 2H 2027.
Why it matters: Interim results will show how well IV Choline Chloride works for patients on parenteral support.
Supportive ifInterim results from the THRIVE-3 trial show positive data on IV Choline Chloride.
Worry ifInterim results from the THRIVE-3 trial are disappointing or delayed.
Why it matters: Updates from the STARBORN-1 trial will inform the potential BLA submission for TARA-002 in LMs.
Supportive ifPositive news from the STARBORN-1 trial helps the BLA submission timeline.
Worry ifNegative updates or delays in the STARBORN-1 trial results.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$191 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $607 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,172 loss on $10,000 · 51.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.